Silk Road Medical Inc (SILK) Expected to Announce Earnings of -$0.28 Per Share

Brokerages predict that Silk Road Medical Inc (NASDAQ:SILK) will post ($0.28) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Silk Road Medical’s earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.26). The business is scheduled to announce its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that Silk Road Medical will report full-year earnings of ($1.75) per share for the current financial year, with EPS estimates ranging from ($2.07) to ($1.43). For the next year, analysts expect that the business will report earnings of ($0.78) per share, with EPS estimates ranging from ($0.89) to ($0.72). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Silk Road Medical.

Silk Road Medical (NASDAQ:SILK) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($7.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($6.67). The company had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $12.28 million.

Several equities analysts have issued reports on SILK shares. BMO Capital Markets started coverage on Silk Road Medical in a research report on Monday, April 29th. They set an “outperform” rating and a $40.01 target price on the stock. Stifel Nicolaus started coverage on Silk Road Medical in a research report on Monday, April 29th. They set a “buy” rating and a $44.00 target price on the stock. JPMorgan Chase & Co. started coverage on Silk Road Medical in a research report on Monday, April 29th. They set an “overweight” rating and a $45.00 target price on the stock. Finally, Bank of America started coverage on Silk Road Medical in a research report on Monday, April 29th. They set a “neutral” rating and a $43.00 target price on the stock. They noted that the move was a valuation call.

In other Silk Road Medical news, major shareholder X Finance L.P. Wp sold 900,000 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $20.00, for a total transaction of $18,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

SILK stock traded down $0.19 during trading on Monday, hitting $42.47. The company had a trading volume of 167,000 shares, compared to its average volume of 207,533. Silk Road Medical has a 1-year low of $30.87 and a 1-year high of $49.55.

Silk Road Medical Company Profile

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

See Also: When is a capital gain realized?

Get a free copy of the Zacks research report on Silk Road Medical (SILK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply